AstraZeneca Suffers 7% Slump Amid 23% Decline in Q4 Net Profit
AstraZeneca Pharma India Shares Plunge 7% Amid Decline in Net Profit
AstraZeneca Pharma India's shares took a significant hit on Wednesday, falling nearly 7 percent in intraday trade after the company reported a 23 percent decline in net profit for the March quarter of FY26. The stock declined 6.76 percent to an intraday low of Rs 8,357 per share on the National Stock Exchange (NSE), snapping a two-day gaining streak following the announcement of its quarterly results.
According to the company's quarterly results, AstraZeneca Pharma India posted a net profit of Rs 44.88 crore for the January-March quarter of FY26, compared with Rs 58.25 crore in the corresponding quarter last year. Despite the decline in net profit, revenue from operations rose 20.42 percent to Rs 578.61 crore during the quarter under review from Rs 480.48 crore a year ago.
Total expenses in the March quarter increased 27.36 percent to Rs 525.34 crore. Market analysts attributed the decline in the stock to profit booking and did not indicate a reversal in the broader trend.
A closer look at the company's performance reveals a mixed bag of results. While the decline in net profit is a cause for concern, the increase in revenue from operations suggests a growth trajectory. Here is a comparison of the company's key financial metrics for the March quarter:
| Quarter | Net Profit (in crores) | Revenue from Operations (in crores) |
|---|---|---|
| FY26 Q3 | Rs 44.88 | Rs 578.61 |
| FY25 Q3 | Rs 58.25 | Rs 480.48 |
For the full FY26, AstraZeneca Pharma India reported a 62 percent rise in net profit to Rs 187.52 crore. Total revenue for the financial year ended March 31 increased 32.58 percent to Rs 2,275.58 crore.
Market analysts remain cautiously optimistic about the company's prospects, citing its ability to sustain above key support levels. Kunal Kamble, Senior Technical Research Analyst at Bonanza Portfolio, noted that the stock is trading in a broad consolidation phase on the weekly chart after a strong uptrend. He highlighted the importance of the stock holding above its key long-term moving averages and the potential for a breakout above the 8,500-8,600 zone to trigger fresh bullish momentum.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Investor Takeaway
Investors should be cautious of profit booking and broader market trends when considering AstraZeneca Pharma India.
More in Market
SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
